Search Press releases Keywords From To 2 Jun 2026 UCB presents research at EUROMIT 2026 highlighting burden of care, need for earlier diagnosis, and impact of pyrimidine nucleoside therapy on people living with TK2d Read More 1 Jun 2026 UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus Read More 19 May 2026 BIMZELX[®](bimekizumab) demonstrates superior efficacy over SKYRIZI[®] (risankizumab) in psoriatic arthritis: BE BOLD Week 16 data Read More 7 May 2026 UCB, Cancer Research UK and Cancer Research Horizons announce new strategic alliance to accelerate development of novel cancer therapies Read More 3 May 2026 UCB to acquire Candid Therapeutics, building upon its existing immunology pipeline with novel T-cell engagers Read More 1 May 2026 UCB announces acquisition of IMIDomics’ Patient Insight Business, strengthening capabilities in immune-mediated inflammatory diseases (IMIDs) Read More Pagination First page Previous page Previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Page 2 of 65 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
